Kinectic Games has released the latest major update for horror game Phasmophobia, and this time, it brings the much-anticipated 6 Tanglewood Drive rework. Tagged by the developers as v016.00, console ...
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...
(RTTNews) - Kite, a Gilead Company (GILD), announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients with relapsed or refractory ...
The FDA has updated the product labeling of capecitabine (Xeloda, Genentech) and fluorouracil to reflect the risks of acute toxicity and potentially fatal adverse reactions in patients with ...
– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – SANTA MONICA, Calif., February 06, ...
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...
WASHINGTON, D.C. — Diabetes patients who use certain TRUE METRIX blood glucose meters are being urged to review updated safety instructions after manufacturer ...
Google Warns Over 1 Billion Android Phones Are Now at Risk Your email has been sent If you’re using an older Android phone, Google has a message you probably don’t want to hear. More than 40% of ...
Timi is a news and deals writer who's been reporting on technology for over a decade. He loves breaking down complex subjects into easy-to-read pieces that keep you informed. But his recent passion ...
The FDA has updated the safety labeling for axicabtagene ciloleucel (Yescarta, Kite Oncology) — a CAR T-cell therapy — extending its indication to include patients with relapsed or refractory primary ...
– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Primary central nervous system lymphoma is ...
Kite, a Gilead Company, today announced the U.S. Food and Drug Administration approved an update to the Yescarta ® prescribing information removing the previous Limitations of Use in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results